MTOR and neoplasm: Rapamycin, an mTOR inhibitor, context-dependently induces senescence (Blagosklonny, 2022), diminishes NF-κB activity (Laberge et al., 2015), suppresses pro-inflammatory SASP translationally, and attenuates senescence-mediated tumor promotion (Wang et al., 2017).